- Home
- ROIV vs CRDO Comparison
ROIV vs CRDO Comparison
Compare ROIV & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | CRDO |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United Kingdom | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 34.2B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CRDO |
|---|---|---|
| Price | $21.54 | $130.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $24.31 | ★ $179.91 |
| AVG Volume (30 Days) | ★ 8.3M | 5.3M |
| Earning Date | 02-09-2026 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.11 |
| Revenue | $20,329,000.00 | ★ $796,128,000.00 |
| Revenue This Year | N/A | $177.26 |
| Revenue Next Year | $741.42 | $37.90 |
| P/E Ratio | ★ N/A | $119.60 |
| Revenue Growth | N/A | ★ 224.17 |
| 52 Week Low | $8.73 | $29.09 |
| 52 Week High | $23.47 | $213.80 |
Technical Indicators
Market Signals| Indicator | ROIV | CRDO |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 34.64 |
| Support Level | $20.78 | $139.88 |
| Resistance Level | $22.21 | $152.00 |
| Average True Range (ATR) | 0.64 | 8.04 |
| MACD | -0.17 | -1.49 |
| Stochastic Oscillator | 26.93 | 16.72 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.